A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis
Authors:
- 1 January 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 20 (5) , 463-484
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease with systemic manifestations. Although the success of immune modulatory drug therapy is considerable, about 40% of patients do not respond to treatment. Mesenchymal stromal/stem cells (MSCs) have been demonstrated to have therapeutic potential for inflammatory diseases. This review provides an update on RA disease and on pre-clinical and clinical studies using MSCs from bone marrow, umbilical cord, adipose tissue, and dental pulp, to regulate the immune response. Moreover, the clinical use, safety, limitations, and future perspective of MSCs in RA are discussed. Using the PubMed database and ClincalTrials.gov, peer-reviewed full-text papers, abstracts and clinical trials were identified from 1985 through to April 2023. MSCs demonstrated a satisfactory safety profile and potential for clinical efficacy. However, it is mandatory to deepen the investigations on how MSCs affect the proinflammatory deregulated RA patients' cells. MSCs are potentially good candidates for severe RA patients not responding to conventional therapies but a long-term follow-up after stem cells treatment and standardized protocols are needed. Future research should focus on well-designed multicenter randomized clinical trials with adequate sample sizes and properly selected patients satisfying RA criteria for a valid efficacy evaluation.Keywords
Funding Information
- Progetto Ricerca Finalizzata 2019 Ministero Salute (project code RF-2019-12370609)
This publication has 274 references indexed in Scilit:
- Modifiable risk factors for RA: prevention, better than cure?Rheumatology, 2011
- Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damageProceedings of the National Academy of Sciences, 2011
- Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNACell Stem Cell, 2010
- Haematopoietic stem and progenitor cells in rheumatoid arthritisRheumatology, 2010
- IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genesMolecular Immunology, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987